Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3840-3849

  Lee, Sang Bong ^a   Hassan, Moinuddin ^b   Fisher, Robert ^c   Chertov, Oleg ^c   Chernomordik, Victor ^b   Kramer Marek, Gabriela ^a   Gandjbakhche, Amir ^b   Capala, Jacek ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c SAIC FREDERICK INC   (United States)

^d Building 10 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOMER; TRASTUZUMAB; ALBUMINOID; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORESCENT DYE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; Z(HER2.4)2 AFFIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONFOCAL MICROSCOPY; CONJUGATE; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VIVO STUDY; MOLECULAR PROBE; MOUSE; NEAR INFRARED IMAGING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TARGET CELL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; DRUG SCREENING; GENETICS; METABOLISM; METHODOLOGY; NEAR INFRARED SPECTROSCOPY; NEOPLASM; NUDE MOUSE; PROTEIN TERTIARY STRUCTURE; PROTO ONCOGENE;

ALBUMINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; FLUORESCENT DYES; GENES, ERBB-2; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SPECTROSCOPY, NEAR-INFRARED; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52449108735     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4076     Document Type: Article

References (46)

1. 1.Slamon DJ, Clark GM, Wong SG. Levin WJ, Ullrich A, McGuire WL Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987:235:177-82.
2. 2.Witton CJ, Reeves JR, Going JJ, CookeTG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003:200:290-7.
3. 3.Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005:5:341-54.
4. 4.Adams GP.Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005:23:1147-57.
5. 5.Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006:5:649-59.
6. 6.Nahta R.Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006,3:269-80.
7. 7.Laudadio J, Quigley Dl.Tubbs R, Wolff DJ. HER2testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn 2007;7:53-64
8. 8.Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overex- pression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552-6.
9. 9.Herschman HR. Molecular imaging: looking at problems, seeing solutions. Science 2003;302:605-8.
10. 10.Olafsen T Kenanova VE, Sundaresan G, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging Cancer Res 2005;65:5907-16
11. 11.Robinson MK, Doss M, Shaller C, et al Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody Cancer Res 2005:65:1471-8.
12. 12.Lundberg E, Hoiden-Guthenberg I, Larsson B, Uhlen M, Graslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 2007:319:53-63
13. 13.Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 2007:7:555-68
14. 14.Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding Affibody ligands Protein Eng Des Sel 2004:17 455-62
15. Perik PJ, Lub-De Hooge MN, Gietema JA, et al lndium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J Clin Oncol 2006:24:2276-82
16. 16.Smith-Jones PM, Solit DB, AkhurstT, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004:22:701 -6.
17. 17.Nilsson FY Tolmachev V Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 2007;10:167-75.
18. 18.Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5:796-806.
19. 19.Shaner NC, Steinbach PA.Tsien RY. A guide to choosing fluorescent proteins. Nat Methods 2005;2:905-9.
20. 20.Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003;7:626-34.
21. 21.Graves EE, Weissleder R, Ntziachristos V. Fluorescence molecular imaging of small animal tumor models. Curr Mol Med 2004;4:419-30.
22. 22.Montet X, Ntziachristos V, Grimm J, Weissleder R. Tomographic fluorescence mapping of tumor targets. Cancer Res 2005;65:6330-6.
23. 23.Tada H, Higuchi H.Wanatabe TM, Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res 2007;67:1138-44.
24. 24.Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res 2006;66:4339-48.
25. 25.Orlova A, Tolmachev V, Pehrson R, et al. Synthetic Affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007;67:2178-86.
26. 26.Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG. Analyzing a kinetic titration series using affinity biosensors. Anal Biochem 2006;349:136-47.
27. 27.Myszka DG. Improving biosensor analysis. J Mol Recognit 1999;12:279-84.
28. 28.Hassan M, Riley J, Chernomordik V, et al. Fluorescence lifetime imaging system for in vivo studies. Mol Imaging 2007;6:229-36.
29. 29.Ekerijung L, Steffen AC, Carlsson J, Lennartsson J. Effects of HER2-binding Affibody molecules on intracellular signaling pathways. Tumour Biol 2006;27:201-10.
30. 30.Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and tras- tuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
31. 31.Mume E, Orlova A, Larsson B, et al. Evaluation of ((4-hydroxyphenyl) ethyl)maleimide for site-specific radiobromination of anti-HER2 Affibody. Bioconjug Chem 2005;16:1547-55.
32. 32.Chernomordik V, Gandjbakhche A, Lepore M, Esposito R, Delfino I. Depth dependence of the analytical expression for the width of the point spread function (spatial resolution) in time-resolved transillumination. J Biomed Opt 2001;6:441-5.
33. 33.ChernomordikV, Hattery DW, Gannot I, Zaccanti G, Gandjbakhche A. Analytical calculation of the mean time spent by photons inside an absorptive inclusion embedded in a highly scattering medium. J Biomed Opt 2002;7:486-92.
34. 34.Dudko OK, Weiss GH, Chernomordik V, Gandjbakhche AH. Photon migration in turbid media with anisotropic optical properties. Phys Med Biol 2004;49:3979-89.
35. 35.Gandjbakhche AH, Chernomordik V, Hattery D, Hassan M, Gannot I. Tissue characterization by quantitative optical imaging methods. Technol Cancer Res Treat 2003;2:537-51.
36. 36.Grosenick D, Moesta KT, Moller M, et al. Time-domain scanning optical mammography. I. Recording and assessment of mammograms of 154 patients. Phys Med Biol 2005;50:2429-49.
37. 37.Rinneberg H, Grosenick D, Moesta KT, et al. Scanning time-domain optical mammography: detection and characterization of breast tumors in vivo. Technol Cancer Res Treat 2005;4:483-96.
38. 38.Choe R, Corlu A, Lee K, et al. Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. Med Phys 2005;32:1128-39.
39. 39.Enfield LC, Gibson AP, Everdell NL, et al.Three-dimensional time-resolved optical mammography of the uncompressed breast. Appl Opt 2007;46:3628-38.
40. 40.Intes X, RipollJ, ChenY, Nioka S.Yodh AG, Chance B. In vivo continuous-wave optical breast imaging enhanced with indocyanine green. Med Phys 2003;30:1039-47.
41. 41.Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A 2000;97:2767-72.
42. 42.Intes X. Time-domain optical mammography SoftScan: initial results. Acad Radiol 2005;12:934-47.
43. 43.Barrett T, Koyama Y, Hama Y, et al. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 2007;13:6639-48.
44. 44.Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res 2007;13:2936-45.
45. 45.Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007;67:254-61.
46. 46.Tolmachev V, Orlova A, Pehrson R, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007;67:2773-82.